United States: Digital Health Law Update Vol. 1 Issue 4

Industry Insights

Are You Ready for Digital-Health Patent Disputes? Getting Strong Patents and Challenging Weak Ones in the Evolving Minefield of U.S. Patent Law

by Doug Pearson, Greg Castanias, Mark Paulson, and Vishal Khatri

With exponential growth occurring in the availability of telemedicine and other digital health products and services, patent disputes are sure to erupt. A recent example is the patent suit filed by American Well, a telemedicine provider, against Teladoc in June 2015, alleging infringement of American Well's patent by Teladoc's telehealth services. The suit was initiated after Teledoc filed an inter partes review ("IPR") petition with the U.S. Patent and Trademark Office ("USPTO") to challenge the validity of the American Well patent in March 2015. In pursuing the IPR proceeding, Teladoc is making use of changes to the U.S. patent law made possible by the America Invents Act, which became effective in 2012.

With the ability to challenge the validity of patents in both federal courts and the USPTO, the need for patent owners to acquire strong patents, and the need for challengers to understand likely areas of weakness, are more important than ever. The terrain is particularly treacherous for computer-implemented inventions (also called software inventions) in light of several recent court decisions addressing, among other things, the subject matter eligible for patenting (Alice Corporation Pty. Ltd. v. CLS Bank International, et al.), whether direct infringement must be attributable to a single entity (Akamai Techs., Inc. v. Limelight Networks, Inc.), and the effect on patent validity/scope of an unintended "means" interpretation (Williamson v. Citrix Online, LLC). While the challenges facing digital health patent holders can be significant given these recent court rulings, they can be overcome in many instances with an eye toward good claim drafting for new and pending patent applications and through possible use of the "reissue" process at the USPTO to correct patent claims before asserting the patent in litigation.

Abstract Ideas. In Alice Corporation Pty. Ltd. v. CLS Bank International, et al., the U.S. Supreme Court set out in June 2014 a two-part test for whether subject matter is eligible for patenting in the first place, which is different from the more commonly known hurdles of novelty and nonobviousness. The test has been applied with devastating effect by district courts and the USPTO to invalidate patents or reject patent claims on grounds that they claim no more than general computer implementations of abstract ideas. With little guidance from the upper courts on (i) what constitutes an "abstract idea" and (ii) what constitutes "significantly more" than the abstract idea under the two-part test, lower courts and the USPTO have struggled. As a practical matter, if the patent claims are not sufficiently technical and are not rooted in computer technology, and instead recite mere implementation of well-known concepts with a general-purpose computer, the claims are likely vulnerable under Alice. While this presents a challenge for those trying to get patent applications on software inventions granted by the USPTO, many issues can be overcome with careful claim drafting. Alice issues can be devastating, however, to patents that were granted before Alice and its recent predecessor cases, and these patents may be candidates for the "reissue" process at the USPTO to have patent claims corrected and reissued before assertion in litigation.

Divided Infringement. The Federal Circuit ruled in May 2015 in Akamai Techs., Inc. v. Limelight Networks, Inc. that direct infringement does not exist where the accused acts are not attributable to a single entity, i.e., are not carried by a single actor, or are not carried out by multiple actors in an agency relationship, contractual relationship, or joint venture. This ruling followed the Supreme Court's decision in June 2014 in Limelight Networks, Inc. v. Akamai Technologies, Inc., where the Supreme Court refused to find indirect patent infringement where there was no underlying direct patent infringement attributable to a single entity. In this case, Akamai had sued Limelight for induced infringement based on the aggregate activities of Limelight and its customers, and although it initially won at the district court and the Federal Circuit, it ultimately lost based on the two subsequent decisions noted above. The cases are important because they underscore the importance of drafting patent claims in a manner to be attributable to a single entity, which is certainly possible in digital health and telemedicine contexts where the inventions may involve the acts of multiple entities. Granted patents that may suffer from divided infringement issues may be candidates for reissue prior to assertion in litigation.

"Means" Interpretation. Under longstanding precedent, when a patent claim has recited in a claim element "means" for carrying out a particular function, there has been a rebuttable presumption that the claim element should be interpreted as a "means-plus-function" element, which by statute limits the scope of the element to the specific structure disclosed in the patent specification for carrying out the claimed function and to equivalents of the disclosed structure. Likewise, there has been a strong presumption that this statutory claim interpretation did not apply where the claim did not recite the word "means." In June 2015 in Williamson v. Citrix Online, LLC, the Federal Circuit overruled precedent regarding the latter and held that the standard is whether "the words of the claim are understood by persons of ordinary skill in the art to have a sufficiently definite meaning as the name for structure." Where a claim element is found to not satisfy the standard (because it recites primarily functional, as opposed to structural, subject matter), the statutory "means" construction applies even if the claim element does not use the word "means." This ruling could have significant impact for digital-health patents and applications where the claim elements are often recited in very functional terms (as opposed to structural terms). On one hand, it could result in certain claim elements being interpreted more narrowly than intended. On the other, it could result in some claims being held invalid as indefinite on grounds that the patent specification does not disclose sufficient structure for carrying out the claimed function. While potential issues may be remedied for patent applications that are pending, patents that have already been granted and that are believed to be vulnerable may be candidates for reissue.

For additional information, see other Jones Day Alerts and Commentaries:

Alice Corp. v. CLS Bank: Did the Supreme Court Sign the Warrant for the "Death of Hundreds of Thousands of Patents"?

Software Inventions—Keeping it Eligible

Divided Federal Circuit Panel Stands by the Single Entity Rule for Direct Patent Infringement

Federal Circuit Upends Presumption for Means-Plus-Function Claiming

Federal Features

21st Century Cures—On July 10, 2015, the U.S. House of Representatives passed H.R.6, the 21st Century Cures Act, focused on reducing regulatory obstacles associated with new pharmaceuticals and medical devices and other innovative therapies. The House bill was approved by a vote of 344–77, and although a companion bill is pending in the Senate, it has yet to advance beyond the committee level. The House action follows months of congressional hearings and negotiations among policymakers and related stakeholders, including with respect to digital health measures. The final bill addresses telehealth mostly in the abstract by requiring the Centers for Medicare & Medicaid Services ("CMS") and the Medicare Payment Advisory Committee (known as MedPac) to submit information to congressional committees regarding barriers to the expansion of telehealth services, results of Medicare telehealth pilot projects, and recommendations for diagnosis and treatment codes that should be covered by telehealth reimbursement. In June 2015, the American Telemedicine Association published recommendations in an effort to bolster the bill's telehealth provisions, including proposals to waive Medicare telehealth restrictions for Accountable Care Organizations ("ACOs") and to align CMS's policies for remote patient monitoring with recent developments in chronic care management services, but the final bill did not feature these provisions. Discussion of telehealth policies could resurface if the Senate considers counterpart legislation.

MSSP "Enabling Technologies"—In June 2015, CMS issued a final rule implementing changes to the Medicare Shared Savings Program ("MSSP"). The rule includes data sharing policies to help ACOs more easily access patient data and encourage greater coordination of care. Under the rule, "enabling technologies" may include electronic health records and other health IT tools; telehealth services, such as remote patient monitoring; electronic exchange of health information; and other electronic tools to engage beneficiaries in their care. The changes are effective November 1, 2015.

Telehealth Legislation—Congress has seen a recent flurry of other bills related to telehealth. Last month, Reps. Mike Thompson (D-CA) and Gregg Harper (R-MS) introduced H.R.2948, the Medicare Telehealth Parity Act of 2015, resurrecting prior proposals by Congress to put telehealth services on a path toward Medicare reimbursement parity with in-person health care. Also, a group led by Reps. Thompson and Morgan Griffith (R-VA) has introduced H.R.2799, the Furthering Access to Stroke Telemedicine (FAST) Act, aimed at expanding access to telestroke treatments. Companion legislation was introduced in the Senate in May 2015. Additionally, Sens. Mark Warner (D-VA), Johnny Isakson (R-GA), and others have proposed S.1549, which features proposals for coverage of 24-hour access emergency support via telemedicine or telephone as part of "advanced illness care coordination services."

EHR/EDC Integration Projects—In June 2015, the Food and Drug Administration ("FDA") announced plans for pilot projects aimed at integrating the often "siloed" data systems used in patient care and clinical research. Electronic health records ("EHRs") are the mainstay of health care practitioners, whereas clinical research for pharmaceutical products increasingly involves data collection and analysis through electronic data capture ("EDC") approaches. FDA's notice requests applications from stakeholders interested in participating in the pilot projects and general comments regarding the use of standards-based technology solutions for eliminating duplication in data capturing and transmission, as well as the facilitation of remote monitoring of data to reduce onsite visits. Applications and comments are due August 10, 2015.

State Summaries

Interstate Medical Licensure Compact—In July 2015, Illinois officially joined the Interstate Medical License Compact ("Compact"), becoming the 11th state to adopt the policy initiative that relaxes certain administrative requirements of licensure for physicians practicing medicine across state lines. Earlier this summer, Minnesota and Nevada adopted the Compact. Follow the status of these state bills and learn about the Compact at licenseportability.org.

Connecticut—On June 23, 2015, Connecticut's governor signed a new law, "Concerning the Facilitation of Telehealth." Effective October 1, 2015, each provider (including physicians and non-physician providers) furnishing services via telehealth to patients in Connecticut must meet certain requirements set out in the statute, including, among others, a specific patient consent, identification of the provider's license number and contact information, and access to the patient's medical record.

Delaware—On July 7, 2015, Delaware enacted a new statute regarding telemedicine services. Effective immediately, the legislation sets out several notable requirements for telemedicine providers, including disclosure of the provider's identity and credentials, patient consent, the provision of a written summary to the patient, and, where the standard of care requires, either an in-person examination or both an audio and visual communication prior to diagnosis and treatment. In contrast to many other similar recent state actions, the Delaware law allows for the prescription of controlled substances through telemedicine in certain circumstances.

Iowa—In June 2015, the Iowa Supreme Court invalidated a recent rule by the state's medical board that had required physicians to conduct in-person examinations prior to administering abortion-inducing drugs. In the opinion, the court held that the rule violates the state constitution by placing an "undue burden" on women located in remote areas, and it also noted that the state already allows telemedicine in other situations.

Maine—In June 2015, the governor of Maine signed a new law allowing the state medical board to register out-of-state licensed physicians to provide medical services via interstate telemedicine to patients located in Maine, if certain requirements are met. The law goes into effect September 15, 2015.

New Hampshire—Effective September 11, 2015, providers delivering telemedicine services in New Hampshire will need to comply with a statute signed into law last month. In particular, the new statute specifies that prescribing without a physician–patient relationship is unprofessional conduct subject to discipline (noting that a physician–patient relationship can be established by either in-person or face-to-face, real-time communication). The statute also limits the prescribing of certain controlled substances based solely on a telemedicine examination.

Reimbursement Review

State Reimbursement—Legislatures in the following states approved telehealth reimbursement measures: Connecticut, Delaware, New Hampshire, Oregon, Texas, and Vermont.

Global Happenings

Data Protection Opinion on Mobile Health

In May 2015, the European Data Protection Supervisor ("EDPS") published an opinion regarding data protection in the age of technological innovation. The opinion aims at drawing attention to the most relevant aspects of data protection for mobile health ("mHealth") that are often, according to the EDPS, overlooked or underestimated. By issuing this opinion, the EDPS hopes to enhance compliance with existing data protection rules and ensure consistent application of such rules. The EDPS makes four key recommendations:

  • In future mHealth policymaking, the EU legislator should foster accountability and allocation of responsibility to those involved in the design, supply, and functioning of apps (including designers and device manufacturers);
  • App designers and publishers should design devices and apps to increase transparency and information in relation to data processing and avoid collecting more data than necessary to perform the expected function by embedding privacy and data protection settings in the design;
  • Industry should utilize "Big Data" in mHealth to benefit app users, as opposed to using it for potentially harmful practices such as discriminatory profiling; and
  • The EU legislator should enhance data security and encourage both the application of privacy by design and the development of building blocks and tools.

Finally, the EDPS explains that because the sector is still largely unregulated, data protection principles and guidance are needed to increase legal certainty and trust in mHealth, and such guidance will contribute to the full development of the mHealth sector.

Health Care Sector Comes Out on Top in Data Protection Eurobarometer Survey

On June 24, 2015, the European Commission published the results of its Data Protection Eurobarometer survey, which was conducted in March 2015. During the course of the survey, almost 28,000 face-to-face interviews were carried out across the European Union with the aim of studying the perceptions of EU citizens on data protection. Although the results show public trust in digital environments remains low, with two-thirds of respondents expressing concern about a lack of control over online information, the health care sector is the most trusted of any sector. Nearly three-quarters of respondents said that they trusted hospitals and medical institutions to protect their personal data, although this figure has declined by 4 percent since the 2010 survey. In contrast, six out of 10 respondents say they do not trust phone companies and internet service providers. The results of the survey will be used to finalize the EU data protection reform.

European Code Related to Privacy and Security in mHealth

The European Commission recently announced plans for a Europe-wide, industry-led Code of Conduct for privacy and security in the mHealth sector. The objective of the Code is to foster citizens' trust in mHealth apps and raise awareness of and facilitate compliance with European data protection rules for app developers. The Code is part of a number of ongoing initiatives from the European Commission in mHealth following a recent industry-wide consultation. Cristiana Spontoni and Indradeep Bhattacharya recently participated in a Q&A with the journal E-health Law and Policy, discussing the Code and what it could mean for the mHealth sector across Europe.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions